Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: STEFAN BABJAK who wrote (374)	5/21/1998 11:58:00 AM
From: Kimberly Lee	Read Replies (2) \| Respond to of 705

NEOT concealed results of tests on two other groups of patients -- WSJ reports. WSJ Health: Neotherapeutics Says Alzheimer's Drug Has Promise as Shares Soar Neotherapeutics Inc. stock doubled in price yesterday after the company announced that Alzheimer's patients showed improvement after one dose of its drug in limited clinical trials. In a physician-sponsored trial in Canada, 10 elderly patients with Alzheimer's disease were given a drug called Neotrofin. "The group showed improvement, but not each individual patient showed improvement," said Steve Runnels, the company's executive vice president. Neotherapeutics, Irvine, Calif., also conducted preliminary tests on two more groups of healthy patients, looking at their tolerance of the drug. THE COMPANY DECLINED TO DISCLOSE RESULTS OF THOSE TRIALS.In a statement, it said the drug "has been able to prevent the subsequent detrimental effects of severe brain damage." Neotherapeutics began recruiting patients for its next level of trials, which it hopes to conclude by year-end so it can determine the correct dosage to use in studies required by the Food and Drug Administration. In Nasdaq Stock Market trading yesterday, shares of Neotherapeutics surged $9.6875 to $19.25. "It's hard to imagine exactly why this happened," Mr. Runnels said of the stock movement. Company chief executive officer Alvin Glasky discussed the findings in Milan. -----------------